FENC

#3025
Fennec Pharmaceuticals Inc. - Common Stock
12.2 7 USD
+0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
12.27
12.27
Intervallo Annuale
5.65
13.25
Variazione giornaliera
+4.25%
Variazione Mensile
+23.94%
Variazione di 6 mesi
+46.59%
Variazione Annuale
+37.09%
Chiusura Precedente
11.7 7
Open
12.2 7
Minimo
12.2 7
Massimo
12.2 7
Volume
36
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Quarterly report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
FENNEC PHARMACEUTICALS INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
FENNEC PHARMACEUTICALS INC. current report, Q1 FY2026
8-K

FENNEC PHARMACEUTICALS INC. current report, 07 July 2009

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Adherex Technologies Inc. (noted as Fennec Pharmaceuticals Inc. in metadata) on July 7, 2009. The filing details a complete restructuring of the Company's Board of Directors and executive management team effective July 7, 2009.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance changes and personnel transitions rather than financial performance data.

Material Changes

  • Board Resignations: All six existing directors (Donald W. Kufe, Michael G. Martin, Fred H. Mermelstein, Robin J. Norris, Peter Morand, and William P. Peters) resigned effective July 7, 2009.
  • CEO Departure: William P. Peters resigned as Chief Executive Officer and entered into a Separation and Mutual Release Agreement.
  • Management Appointments:
    • Robert Butts appointed Chairman of the Board.
    • Rosty Raykov appointed Director and Chief Executive Officer.
    • Robert Andrade appointed Director and Vice President.
    • Thomas Spector appointed Chief Scientific Officer.
  • Compensation Changes: New appointees Rosty Raykov and Robert Andrade agreed to work temporarily without salary. No related party transactions were disclosed for the new management team.
  • Termination: D. Scott Murray was terminated effective July 10, 2009, with no material severance intended.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, forward-looking statements regarding revenue or profitability, or a discussion of specific business risks. The primary focus is the transition of leadership to individuals with backgrounds in private investment (Raykov and Andrade) and drug discovery (Spector). Dr. Spector is noted as the principal inventor of the eniluracil/5-fluorouracil treatment for cancer.

Investor Verification Checklist

  • Verify the terms of the Separation and Mutual Release Agreement with former CEO William P. Peters (Exhibit 10.23).
  • Confirm the duration of the temporary unpaid status for new CEO Rosty Raykov and VP Robert Andrade.
  • Review the press release (Exhibit 99.1) for strategic rationale behind the leadership overhaul.
  • Assess the Company's current cash runway given the lack of disclosed financial metrics in this report.

Notizie